Polaryx Therapeutics, Inc. Common Stock (PLYX)
Polaryx Therapeutics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Paramus, NJ, US. The stock last traded at $2.09, down 2.34% on the session, giving a market capitalisation of $104.2M. On trailing twelve-month figures it carries a trailing P/E of -17.17, a net margin of 0.0%. Its beta of -9.26 implies it has historically moved less than the broad market.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Polaryx Therapeutics, Inc. Common Stock is most often compared with the following Healthcare names: